-
Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab
Tuesday, February 1, 2022 - 11:03am | 286Read More...Biogen Inc (NASDAQ: BIIB) has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispecific antibody for B-cell non-Hodgkin's lymphoma (NHL), including follicular lymphoma (FL) and diffuse large B-cell...
-
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
Tuesday, November 30, 2021 - 2:07pm | 288Read More...TG Therapeutics Inc (NASDAQ: TGTX) shares are falling after FDA notified the Company that it plans to host an Oncologic Drugs Advisory Committee (ODAC) meeting for marketing application regarding ublituximab/ Ukoniq (umbralisib) (U2 combo). U2 Combo application seeks approval for chronic...
-
MEI Pharma, Kyowa Kirin Reveal Data From Zandelisib Trial In Follicular Lymphoma
Tuesday, November 30, 2021 - 11:09am | 261Read More...MEI Pharma Inc (NASDAQ: MEIP) and Kyowa Kirin Co Ltd have announced data from the pivotal Phase 2 TIDAL study of zandelisib as a single agent for follicular lymphoma (FL) patients who received at least two prior systemic therapies. Data demonstrated a 70.3% objective...
-
HUTCHMED's Lymphoma Candidate Secures Breakthrough Tag In China
Monday, September 13, 2021 - 6:22am | 223Read More...The Center for Drug Evaluation of China's National Medical Products Administration has granted Breakthrough Therapy Designation to HUTCHMED (China) Limited's (NASDAQ: HCM) amdizalisib (HMPL-689). The selective and potent PI3Kδ inhibitor is being developed for...
-
Gilead's Kite Pharma Earns FDA Nod For Yescarta For Type Of Blood Cancer
Monday, March 8, 2021 - 6:39am | 208Read More...The FDA has granted accelerated approval to Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma's 'Yescarta' (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of...
